The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia

Cancer Research

Volumn 70, Issue 8, 2010, Pages 3080-3088

  Ke, Hengning ^a   Harris, Rebecca ^a   Coloff, Jonathan L ^a   Jin, Jane Y ^a   Leshin, Benjamin ^a   De Marval, Paula Miliani ^a   Tao, Shiying ^b   Rathmell, Jeffrey C ^a   Hall, Russell P ^a   Zhang, Jennifer Y ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 9; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; STRESS ACTIVATED PROTEIN KINASE; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; RAS PROTEIN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENZYME INHIBITION; EPIDERMIS CELL; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; ANIMAL; BIOLOGICAL MODEL; BIOPSY; CELL AGING; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; BIOPSY; CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 9; MODELS, BIOLOGICAL; RAS PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 77951037489     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2923     Document Type: Article

References (46)

1. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912
2. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252
3. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001;15:1419-1426 (Pubitemid 32524648)
4. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007;13:1875-1886 (Pubitemid 47010160)
5. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Matsuhisa M, Yamasaki Y. Oxidative stress and the JNK pathway in diabetes. Curr Diabetes Rev 2005;1:65-72.
6. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47:409-414
7. Chen N, Nomura M, She QB, et al. Suppression of skin tumorigenesis in c-Jun NH2-terminal kinase-2-deficient mice. Cancer Res 2001;61:3908-3912 (Pubitemid 32720949)
8. Tsuiki H, Tnani M, Okamoto I, et al. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 2003;63:250-255 (Pubitemid 36070447)
9. Yang YM, Bost F, Charbono W, et al. C-Jun NH2-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9:391-401. (Pubitemid 36109757)
10. Papachristou DJ, Batistatou A, Sykiotis GP, Varakis I, Papavassiliou AG. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 2003;32:364-371 (Pubitemid 36407536)
11. 2-kinase signaling promotes human neoplasia. Cancer Res 2007;67:3827-3834
12. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-429
13. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003;2:554-565
14. BogoyevitchMA. The isoform-specific functions of the c-Jun N-terminal kinases (JNKs): differences revealed by gene targeting. BioEssays 2006;28:923-934
15. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev 1999;89:115-124 (Pubitemid 29528280)
16. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 1999;22:667-676 (Pubitemid 29203491)
17. Sabapathy K, Wagner EF. JNK2: a negative regulator of cellular proliferation. Cell Cycle 2004;3:1520-1523 (Pubitemid 40521404)
18. Weston CR, Wong A, Hall JP, Goad ME, Flavell RA, Davis RJ. The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci U S A 2004;101:14114-14119 (Pubitemid 39305039)
19. 2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 2002;62:1343-1348
20. Katagiri C, Negishi K, Hibino T. c-JUN N-terminal kinase-1 (JNK1) but not JNK2 or JNK3 is involved in UV signal transduction in human epidermis. J Dermatol Sci 2006;43:171-179 (Pubitemid 44189198)
21. Dajee M, Lazarov M, Zhang JY, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-643 (Pubitemid 36227672)
22. Mirella Lazarov YK, Cai T, Dajee M, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002;8:1105-1114 (Pubitemid 35175965)
23. Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett 2009;276:125-135
24. Treier M, Bohmann D, Mlodzik M. JUN cooperates with the ETS domain protein pointed to induce photoreceptor R7 fate in the Drosophila eye. Cell 1995;83:753-760
25. Han S-Y, Kim S-H, Heasley LE. Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts. J Biol Chem 2002;277:47167-47174
26. Derijard B, Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994;76:1025-1037 (Pubitemid 24106383)
27. Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA. In vivo restoration of laminin 5 β3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A 2001;98:5193-5198
28. Zhang JY, Tao S, Kimmel R, Khavari PA. CDK4 regulation by TNFR1 and JNK is required for NF-κB-mediated epidermal growth control. J Cell Biol 2005;168:561-566 (Pubitemid 40271021)
29. Caruccio L, Banerjee R. An efficient method for simultaneous isolation of biologically active transcription factors and DNA. J Immunol Methods 1999;230:1-10.
30. Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 2001;276:12041-12048 (Pubitemid 37385367)
31. Liu J, Minemoto Y, Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor α-induced c-Jun kinase activation and apoptosis. Mol Cell Biol 2004;24:10844-10856 (Pubitemid 39603140)
32. 2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport. J Biol Chem 1998;273:800-804
33. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
34. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-531
35. Sharpless NE. Ink4a/Arf links senescence and aging. Exp Gerontol 2004;39:1751-1759
36. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260 (Pubitemid 28183365)
37. Seitz CS, Freiberg RA, Hinata K, Khavari PA. NF-κB determines localization and features of cell death in epidermis. J Clin Invest 2000;105:253-260 (Pubitemid 30094444)
38. Reiss M, Brash DE, Munoz-Antonia T, et al. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 1992;4:349-357 (Pubitemid 23167119)
39. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270
40. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-1653
41. Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett 2008.
42. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 2005;70:363-374
43. Lang JC, Tobin EJ, Knobloch TJ, et al. Frequent mutation of p16 in squamous cell carcinoma of the head and neck. Laryngoscope 1998;108:923-928 (Pubitemid 28299913)
44. Choi BY, Choi HS, Ko K, et al. The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat Struct Mol Biol 2005;12:699-707. (Pubitemid 43086276)
45. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-317 (Pubitemid 33097808)
46. Deng H, Yu F, Chen J, Zhao Y, Xiang J, Lin A. Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J Biol Chem 2008;283:20754-20760